Recent advances in allergen immunotherapy
Wei Fu, Yang Zheng, Hao Chen, Xiang Dong, Wei Li, Huiling Liang, Shiwei Chen, Cezmi A Akdis, Yadong Gao · 2026
Read Recent advances in allergen immunotherapy by Wei Fu, Yang Zheng, Hao Chen, Xiang Dong, Wei Li, Huiling Liang, Shiwei Chen, Cezmi A Akdis, Yadong Gao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13544763.txt.
Description
Wei Fu and colleagues published a 2026 review of recent advances in allergen immunotherapy, the only treatment that can retrain the immune system rather than merely suppress allergy symptoms. The therapy now serves hay fever, asthma, food allergy, and eczema driven by IgE antibodies. The review covers the tolerance machinery, new vaccine designs, response biomarkers, disease-by-disease evidence, and combinations with modern biologic drugs.
Tolerance is built by regulatory T and B cells, calming innate lymphoid cells, and blocking antibodies such as IgG4. Newer vaccines use engineered or hypoallergenic allergens, virus-like particles, and peptide designs to gain safety and speed. Candidate blood and cell tests for predicting response are weighed critically. Pairing immunotherapy with anti-IgE or anti-interleukin biologics looks promising in severe asthma. Patient selection, treatment length, and extract standardisation remain the field's open problems.
Catalog record
| CREATOR | Wei Fu, Yang Zheng, Hao Chen, Xiang Dong, Wei Li, Huiling Liang, Shiwei Chen, Cezmi A Akdis, Yadong Gao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 63969 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |